Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bictegravir

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

GSK’s momelotinib recommended by CHMP to treat myelofibrosis patients with anaemia

About 40% of patients have moderate-to-severe anaemia at the time of diagnosis

- PMLiVE

GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal

GSK will evaluate the therapy in combination with its own hepatitis B treatment

- PMLiVE

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

GSK’s RSV vaccine Arexvy shows promise in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

- PMLiVE

GSK survey results highlight meningitis knowledge gaps among parents

More than 90% of parents did not know all three common symptoms of the infection

- PMLiVE

Gilead’s Veklury recommended by CHMP for COVID-19 in patients with hepatic impairment

If approved, Veklury would become the first COVID-19 antiviral authorised for use across all stages of liver disease

- PMLiVE

GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia

Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

Gilead and Arcus drop A2R inhibitor in prostate cancer following early data analysis

The candidate is also being evaluated in second- and third-line metastatic colorectal cancer

- PMLiVE

GSK discovers strain of bacterium that stops malaria transmission

It is hoped that the discovery could contribute to the eradication of the disease

- PMLiVE

GSK files lawsuit against Pfizer over RSV vaccine patent infringement

The RSV vaccine market is estimated to exceed $5bn and could surpass $10bn by 2030

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links